HM1: Update on EU new regulatory legislation − EMA, industry and others


Olga Solomon highlighted the Commission proposals in relation to the reform of the EU pharmaceutical legislation, and notably the package adopted by the Commission in April 2023 which includes a new Regulation and a new Directive as well as an initiative aimed at preventing antimicrobial resistance (AMR). She reminded the session audience that the political objectives of this ambitious reform were to improve access to medicines in the EU, strengthen measures to prevent shortages of medicinal products and secure the supply of critical products, while reinforcing affordability for patients and ensuring environmental sustainability. These measures were prepared keeping in mind that they should not negatively impact the capacity of innovation of the pharmaceutical industry and maintain competitiveness.

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.

Members login

Included with TOPRA membership

Already a TOPRA member?

Using your MyTOPRA credentials, log-in now for unlimited access to all Regulatory Rapporteur journal articles, online archive and the latest industry news and content.



Free access to selected content

Register to continue to access industry news, podcasts and commentary plus one member-only journal article each month. You will still be able to view editorials and contents pages without restriction.

  • Create your own library to save your favourite content.
  • Sign up for Regulatory Rapporteur email newsletters.
Create a free account


TOPRA membership

Become a TOPRA member and join our global community of regulatory affairs professionals.

  • Great savings on our events and training.
  • Be part of our dynamic international community.
  • Contribute to the profession.
  • Grow your skills and knowledge.
  • Take your career to the next level.
Become a member